12
NEWS
Diabeloop &
NovoPens
Diabeloop (DBL) announces
collaboration with Novo Nordisk to
pursue its interoperability strategy
with connected insulin pens. The
agreement covers integrating DBL4penTM,
Diabeloop's self-learning
algorithm for MDI therapy, with
Novo Nordisk's connected and
reusable insulin pens, NovoPen®
6 and NovoPen Echo® Plus.
Diabeloop is planning a dedicated
study for people living with Type 2
diabetes to evaluate the efficacy and
clinical benefits of the combined
technologies.
DBL-4pen is a self-learning basal
and bolus recommendation app
for people with Type 1 and Type 2
diabetes who take multiple daily
insulin injections (MDI). NovoPen
6 and NovoPen Echo Plus are
connected pens with a dose memory
function that keeps a history of
the last 800 insulin injections and
shows on a built-in digital display
the number of units administered
during the last injection, as well as
the time since that injection. Data
transfer from the connected pen to
an external device is based on Near
Field Communication (NFC). At the
moment these connected pens are
the only ones to be covered by public
health insurance in France.
The common commitment of the
two companies to bring innovative
solutions for diabetes management
to patients has driven the conclusion
of this agreement.
Diabeloop is also working on a
clinical program with Type 2 diabetes
patients. The clinical program will
start with an initial multi-brand,
multi-centre, before/after 14-week
clinical trial that aims to assess the
efficacy and safety of the DBL-4pen
mobile application on glycaemic
control in patients with Type 2
diabetes. It will include forty patients
with T2D across four hospitals
in France.
The self-learning algorithm will
recommend the dose of insulin to
be injected from input data such
as meals and exercise. This trial
program is shaping Diabeloop's
future projects for MDI therapy.
Diabeloop plans to address first
the Type 2 population on intensive
insulin treatment before soon
expanding to people with Type 1
diabetes who do not have access to
or desire to wear an insulin pump.
Thomas Thestrup-Terp,
Corporate Vice President, Digital
Strategy and Solutions, Novo
Nordisk, said: "Smart insulin pens
offer digital connectivity for people
living with diabetes and the potential
to automatically recommend the
ideal insulin dose in real-time. This
could significantly improve the way
diabetes medicines are used."
Christine Massien, Diabetes
Medical Director within Novo
Nordisk France added, "Novo
Nordisk France is pleased to support
Diabeloop, a French company that
has developed the first 'closed-loop'
solution for patients treated with
MDI. Novo Nordisk is thus supporting
a game-changing company, in order
to accelerate the CE marking of its
new solution. We look forward to
providing patients with a reliable
solution that will take the NovoPen
6 and NovoPen Echo Plus from
'connected' to 'smart'
www.diabeloop.com